Taiwan, August 6, 2026
Senhwa Biosciences, Inc. has received Taiwan Food and Drug Administration (TFDA) clearance for a multicenter Phase 1b/2a clinical trial evaluating pidnarulex (CX-5461) in combination with a marketed PD-1 immune checkpoint inhibitor in patients with advanced solid tumors. The regulatory milestone follows U.S. FDA clearance of the study in June 2026, enabling the clinical program to proceed in both Taiwan and the United States. The trial represents Senhwa’s first multicenter combination study pairing CX-5461 with a PD-1 inhibitor and marks an important expansion of the investigational therapy from a DNA-targeting anticancer candidate toward a potential immuno-oncology combination strategy. The study will assess safety, tolerability and preliminary antitumor activity in patients with pancreatic cancer, colorectal cancer and melanoma, including individuals whose tumors have developed resistance to previous immune checkpoint inhibitor treatment.
CX-5461 and PD-1 Combination Targets Resistant Tumors
The scientific rationale for the trial centers on the challenge of primary and acquired resistance to PD-1/PD-L1 checkpoint inhibitors. Although checkpoint blockade has transformed treatment across multiple cancers, many patients either fail to respond initially or experience disease progression after an earlier response. This problem can be particularly pronounced in so-called immune-cold tumors, where limited immune-cell infiltration, inadequate antigen presentation and an immunosuppressive tumor microenvironment can restrict effective antitumor immunity. Senhwa’s Phase 1b/2a study will investigate whether combining CX-5461 with PD-1 inhibition can potentially alter these conditions and improve immune recognition of cancer cells. The trial will also explore whether the combination can restore antitumor immune activity among patients whose cancers have become resistant to previous checkpoint therapy. These effects remain clinical hypotheses and must be demonstrated through prospective clinical data.
Pidnarulex May Enhance Tumor Immune Sensitivity
Pidnarulex (CX-5461) is Senhwa’s first-in-class investigational agent designed to induce DNA replication stress and DNA damage responses in cancer cells. Beyond directly disrupting cancer-cell survival, emerging research cited by the company suggests that these mechanisms could promote immunogenic cell death, stimulate innate immune signaling and increase immune activity within the tumor microenvironment. This provides the biological rationale for investigating CX-5461 as a potential immune-sensitizing partner for PD-1 blockade. The study will examine whether treatment can increase immune-cell infiltration and antigen presentation and potentially make immune-cold tumors more susceptible to immune-mediated attack. The program is being conducted under a collaboration model in which an undisclosed global pharmaceutical company is supplying the marketed PD-1 inhibitor, while Senhwa leads the global development and regulatory activities associated with the study. The combination of U.S. FDA and Taiwan TFDA clearances provides an internationally aligned framework for the early-stage clinical evaluation.
Advertisement
Dual Regulatory Clearance Expands Global Clinical Development
The Phase 1b/2a program could have strategic implications beyond the initial tumor types if clinical results establish an acceptable safety profile and provide evidence of antitumor activity. Senhwa believes that positive findings could support investigation of CX-5461 alongside additional PD-1 or PD-L1 therapies and potentially other cancer treatment modalities, although such applications remain prospective. The current trial remains early-stage and is primarily intended to characterize safety, tolerability, pharmacologic effects and preliminary efficacy rather than establish definitive clinical benefit. Senhwa plans to use emerging safety, efficacy, pharmacologic and biomarker data to identify patient populations and development strategies that may warrant further investigation. The inclusion of pancreatic cancer and colorectal cancer is particularly relevant to the broader effort to improve immunotherapy responses in tumors where checkpoint inhibitors may have limited effectiveness for many patients, while the melanoma cohort offers another setting for investigating acquired immunotherapy resistance. With regulatory clearance now secured in both Taiwan and the United States, Senhwa can advance site activation and patient enrollment for its first multicenter CX-5461 and PD-1 combination trial. The program represents an important clinical milestone for the company as it evaluates whether DNA replication stress can be leveraged to broaden the effectiveness of established cancer immunotherapies.
Source: Senhwa Biosciences press release
